HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook
Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidates Follow-on offering strengthened cash basis with $143 million available at year-end to support …